Artificial Antigen-Presenting Cells in Cancer Immunotherapy

Artificial antigen-presenting cells (aAPCs) are engineered constructs designed to emulate the functions of professional antigen-presenting cells. By displaying tumour-associated peptide–MHC complexes alongside co-stimulatory ligands and, in some designs, tethered or paracrine cytokines, aAPCs aim to prime and expand antigen-specific T lymphocytes for adoptive cell therapy or in vivo immunomodulation. Compared with autologous dendritic or monocyte-derived platforms, synthetic aAPCs offer scalable manufacturing, batch-to-batch consistency and the ability to tune biophysical parameters such as particle size, shape, ligand density and cytokine release kinetics. Recent innovations include intracellularly gelated cell membranes that preserve native surface proteins, affinity-bead systems capturing the full repertoire of tumour peptide–MHCs from lysates and nanoscale polymeric or liposomal scaffolds with defined topology. These advances have demonstrated control over CD8+ cytotoxic responses, CD4+ helper subsets and activation-induced cell death, paving the way for off-the-shelf immunotherapies across solid tumours and haematological malignancies.

Research from Nature Portfolio

One study introduced an intracellular hydrogelation approach to stabilise cell membranes post-lysis, yielding robust aAPCs that retain fluid lipid bilayers, protein mobility and native co-stimulatory molecules. These gelated cells effectively engaged antigen-specific T cells ex vivo and enhanced expansion and cytotoxic function in murine models. Another report described a rapid, one-step aAPC fabrication using affinity beads to capture endogenous peptide–MHC complexes directly from tumour cell lysates. The resulting cell-free constructs elicited broad antigen-specific CD8+ T cell responses and achieved in vivo tumour regression, demonstrating a cost-effective route to patient-specific cancer vaccines without recombinant MHC production.

Artificial Antigen-Presenting Cells in Cancer Immunotherapy publication trend

The graph below shows the total number of articles in artificial antigen-presenting cells in cancer immunotherapy across all publications each year (not limited to Nature Index journals).

Technical terms

Artificial antigen-presenting cell (aAPC): An engineered material or cell fragment displaying antigen–MHC complexes and co-stimulatory signals to activate T cells.

Major histocompatibility complex (MHC): A cell surface protein that presents peptide antigens to T cell receptors.

Co-stimulatory molecule: A surface ligand (e.g., CD80, CD86) required alongside antigen–MHC engagement to fully activate T cells.

Cytokine: A soluble protein (e.g., IL-2) that modulates immune cell proliferation, differentiation and survival.

Immunological synapse: The organised interface between T cell and APC where signalling molecules cluster to initiate activation.

Polymersome: A self-assembled vesicle formed from amphiphilic block copolymers, used as a nanocarrier for antigen and ligand presentation.

References

1. An Artificial Antigen-presenting Cell with Paracrine Delivery of IL-2 Impacts the Magnitude and Direction of the T Cell Response*. Journal of Biological Chemistry (2011).
2. Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells. Trends in Biotechnology (2014).
3. Intracellular hydrogelation preserves fluid and functional cell membrane interfaces for biological interactions. Nature Communications (2019).
4. One-step artificial antigen presenting cell-based vaccines induce potent effector CD8 T cell responses. Scientific Reports (2019).
5. Artificial Antigen-Presenting Cell Topology Dictates T Cell Activation. ACS Nano (2022).
6. Polymeric Systems for Cancer Immunotherapy: A Review. Frontiers in Immunology (2022).